Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Are novel therapeutics replacing ASCT?

Hermann Einsele • 14 Sep 2019
IMW 2019
Multiple Myeloma

Prof. Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, outlines which patient populations allogeneic stem cell transplantations (ASCT) are most relevant, and whether novel therapeutics now challenge this. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Hermann Einsele

2:44
Moving CAR-T into earlier lines of therapy in multiple myeloma
Hermann Einsele • 17 Feb 2024
0:45
CAR T-cell therapy in lenalidomide-refractory multiple myeloma
Hermann Einsele • 17 Feb 2024
1:19
Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myeloma
Hermann Einsele • 26 Jun 2023
8:16
Results from CARTITUDE-4: cilta-cel for lenalidomide-refractory multiple myeloma
Hermann Einsele • 26 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals